National Cancer Center Cancer Information Service: Projected cancer statistics. 2025. https://ganjoho.jp/reg_stat/statistics/stat/short_pred_en.html

Wang J, Li B, Luo M, Huang J, Zhang K, Zheng S, Zhang S, Zhou J. Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance. Signal Transduct Target Therapy. 2024;9(1):83.

Article  CAS  Google Scholar 

Tada K, Kumamaru H, Miyata H, Asaga S, Iijima K, Ogo E, Kadoya T, Kubo M, Kojima Y, Tanakura K, et al. Characteristics of female breast cancer in Japan: annual report of the National Clinical Database in 2018. Breast Cancer. 2023;30(2):157–66.

Article  PubMed  Google Scholar 

Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7(5):e1000279.

Article  PubMed  PubMed Central  Google Scholar 

Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomark Prev. 2018;27(6):619–26.

Article  CAS  PubMed  Google Scholar 

NCCN Guidelines - Breast Cancer: https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients

National Institute for Health and Care Excellence, Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (HTG719). 2024. . https://www.nice.org.uk/guidance/htg719

Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E, clinicalguidelines@esmo.org egcea. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger. Ann Oncol. 2019;30(8):1194–220.

Andre F, Ismaila N, Allison KH, Barlow WE, Collyar DE, Damodaran S, Henry NL, Jhaveri K, Kalinsky K, Kuderer NM, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2022;40(16):1816–37.

Article  CAS  PubMed  Google Scholar 

Panel NIoHCD. National institutes of health consensus development conference statement: adjuvant therapy for breast cancer, November 1–3, 2000. JNCI Monogr. 2001;2001(30):5–15.

Article  Google Scholar 

Terada M, Ito A, Kikawa Y, Koizumi K, Naito Y, Shimoi T, Ishihara M, Yamanaka T, Ozaki Y, Hara F, et al. The Japanese breast cancer society clinical practice guidelines for systemic treatment of breast cancer, 2022 edition. Breast Cancer. 2023;30(6):872–84.

Article  PubMed  PubMed Central  Google Scholar 

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, et al. Adjuvant chemotherapy guided by a 21-Gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor–positive breast cancer. J Clin Oncol. 2006;24(23):3726–34.

Article  CAS  PubMed  Google Scholar 

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817–26.

Article  CAS  PubMed  Google Scholar 

Yamauchi H, Nakagawa C, Yamashige S, Takei H, Yagata H, Yoshida A, Hayashi N, Hornberger J, Yu T, Chao C, et al. Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in Japan. BMC Health Serv Res. 2014;14:372.

Article  PubMed  PubMed Central  Google Scholar 

Berdunov V, Cuyun Carter G, Laws E, Luo R, Russell CA, Campbell S, Abdou Y, Force J. Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score® test from a US societal perspective. ClinicoEcon Outcomes Res 2024:16 471–82.

Berdunov V, Millen S, Paramore A, Griffin J, Reynia S, Fryer N, Brown R, Longworth L. Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score® test in node-negative early breast cancer. Clinicoecon Outcomes Res. 2022;14:619–33.

Article  PubMed  PubMed Central  Google Scholar 

Kondo M, Hoshi SL, Yamanaka T, Ishiguro H, Toi M. Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03). Breast Cancer Res Treat. 2011;127(3):739–49.

Article  PubMed  Google Scholar 

Guideline for Preparing Cost-Effectiveness Evaluation to the Central Social Insurance Medical Council. 2022. https://c2h.niph.go.jp/tools/guideline/guideline_en.pdf

Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019;380(25):2395–405.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shimomura A, Sagara Y, Koto R, Fujiwara M, Kanemura Y, Kitagawa H, Saji S. Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan. Breast Cancer (2024) 31: 581-592.

Geyer CE Jr., Tang G, Mamounas EP, Rastogi P, Paik S, Shak S, Baehner FL, Crager M, Wickerham DL, Costantino JP, et al. 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. NPJ Breast Cancer. 2018;4:37.

Article  PubMed  PubMed Central  Google Scholar 

De Bock G, Putter H, Bonnema J, Van Der Hage J, Bartelink H, Van De Velde C. The impact of loco-regional recurrences on metastatic progression in early-stage breast cancer: a multistate model. Breast Cancer Res Treat. 2009;117:401–8.

Article  CAS  PubMed  Google Scholar 

Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S. Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis. Breast Cancer Res Treat. 2012;135(2):335–46.

Article  CAS  PubMed  Google Scholar 

Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, Allison M, Hemingway H, Cleland JG, McMurray JJV, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. 2018;391(10120):572–80.

Article  PubMed  Google Scholar 

Hall PS, Smith A, Hulme C, Vargas-Palacios A, Makris A, Hughes-Davies L, Dunn JA, Bartlett JMS, Cameron DA, Marshall A, et al. Value of information analysis of multiparameter tests for chemotherapy in early breast cancer: the OPTIMA prelim trial. Value Health. 2017;20(10):1311–8.

Article  PubMed  Google Scholar 

Abridged Life Tables for Japan. 2022. https://www.mhlw.go.jp/english/database/db-hw/lifetb22/dl/lifetb22-06.pdf

Inoue K, Masuda N, Iwata H, Takahashi M, Ito Y, Miyoshi Y, Nakayama T, Mukai H, van der Walt J-S, Mori J. Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. Breast Cancer. 2021;28:1038–50.

Article  PubMed  PubMed Central  Google Scholar 

Taylor CJ, Ordóñez-Mena JM, Roalfe AK, Lay-Flurrie S, Jones NR, Marshall T, Hobbs FDR. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000–2017: population based cohort study. BMJ 2019; 364: l223. https://doi.org/10.1136/bmj.l223

Ministry of Health Labour and Welfare (MHLW). Insurance coverage of medical devices. 2024. https://www.mhlw.go.jp/content/12404000/001117408.pdf

Ministry of Health Labour and Welfare (MHLW). Medical fees 2024 and appendix 1 - medical treatment fee schedule 2024. 2024. https://www.mhlw.go.jp/content/12404000/001065988.pdf, https://www.mhlw.go.jp/content/12404000/000907836.pdf, https://www.mhlw.go.jp/content/12404000/000907834.pdf, https://www.mhlw.go.jp/content/12404000/000907834.pdf

Ueno R, Nishimura S, Fujimoto G, Ainiwaer D. Healthcare resource utilization and economic burden of antifungal management in patients with hematologic malignancy in Japan: a retrospective database study. Curr Med Res Opin. 2021;37(7):1121–34.

Article  PubMed  Google Scholar 

Hashimoto Y, Hayashi A, Teng L, Igarashi A. Real-world cost-effectiveness of palliative care for terminal cancer patients in a Japanese general hospital. J Palliat Med. 2021;24(9):1284–90.

Article  PubMed  Google Scholar 

Nakao Y, Kawakami H, Saito M, Inoue K, Ikeda S, Yamaguchi O. Cost-effectiveness of long-term tolvaptan administration for chronic heart failure treatment in Japan. J Cardiol. 2022;79(3):408–16.

Article  PubMed  Google Scholar 

Report on the Consumer Price Index: 2025 . https://www.stat.go.jp/english/data/cpi/1588.html#nen

Watanabe T, Kuranami M, Inoue K, Masuda N, Aogi K, Ohno S, Iwata H, Mukai H, Uemura Y, Ohashi Y. Comparison of an AC-taxane versus AC‐free regimen and Paclitaxel versus docetaxel in patients with lymph node‐positive breast cancer: final results of the National Surgical Adjuvant Study of breast cancer 02 trial, a randomized comparative phase 3 study. Cancer. 2017;123(5):759–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fujii T, Le Du F, Xiao L, Kogawa T, Barcenas CH, Alvarez RH, Valero V, Shen Y, Ueno NT. Effectiveness of an adjuvant chemotherapy regimen for early-stage breast cancer: a systematic review and network meta-analysis. JAMA Oncol. 2015;1(9):1311–8.

Article  PubMed  PubMed Central  Google Scholar 

Iwatani T, Noto S, Tsugawa K. Correlation analysis between health state values derived from EQ-5D-5L and EQ-VAS in Japanese breast cancer patients. Value Health. 2017;20(9):A449–50.

Article